Non-insulin-dependent diabetes mellitus (Type II diabetes). Adults, initial: 1-2 mg once daily, given with breakfast or the first main meal. The initial dose should be 1 mg in those sensitive to hypo-glycemic drugs, in those with impaired renal or hepatic function, and in elderly, debilitated, or malnourished clients. The maximum initial dose is 2 mg or less daily. Maintenance: 1-4 mg once daily up to a maximum of 8 mg once daily. After a dose of 2 mg is reached, the dose should be increased in increments of 2 mg or less at 1- to 2-week intervals (determined by the blood glucose response). When combined with insulin therapy: 8 mg once daily with the first main meal with low-dose insulin. The fasting glucose level for beginning combination therapy is greater than 150 mg/dL glucose in the plasma or serum.
Type II diabetes—transfer from other hypoglycemic agents. When transferring clients to glim-ipiride, no transition period is required. However, clients should be observed closely for 1 to 2 weeks for hypoglycemia when being transferred from longer half-life sulfony-lureas (e.g., chlorpropamide) to glimepiride.
Was this article helpful?
Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...